Red-cell lysis releases the hemoglobin contained within erythrocytes into the measured sample. That step makes the total hemoglobin available for optical analysis rather than leaving it enclosed in intact cells. The resulting sample can then be evaluated by spectrophotometry, allowing the measured signal to represent hemoglobin across the blood volume being analyzed.
A stabilized hemoglobin derivative provides an alternative optical measurement form after red-cell lysis. The assay therefore does not depend exclusively on measuring hemoglobin in its initially released state. Spectrophotometric absorbance of either the released hemoglobin or the stabilized derivative is used to determine the amount present in the sampled blood volume.
A higher or lower amount per blood volume changes the oxygen-transport capacity represented by that sample. For bioengineered systems, the measurement provides a quantitative basis for examining whether altered red-cell composition, blood substitutes, or oxygen-carrying biomaterials could support oxygen delivery. It can therefore connect composition measurements with overall physiological performance.
A typical workflow begins with a blood sample, followed by red-cell lysis. The released hemoglobin, or a stabilized hemoglobin derivative, is then assessed through spectrophotometry by measuring absorbance. The result is interpreted as an amount of hemoglobin relative to the analyzed blood volume, which allows comparisons among samples or engineered conditions.
Total Hemoglobin Concentration supports evaluation of blood substitutes, oxygen-carrying biomaterials, microfluidic systems, and tissue-engineered constructs. In each setting, the measurement helps characterize the hemoglobin available within the system or sample. That information can be used alongside engineered changes to consider potential effects on oxygen delivery and overall physiological performance.
By quantifying hemoglobin in a defined blood volume, the assay gives a common measurement for comparing conditions associated with anemia, blood loss, or altered red-cell composition. In bioengineering studies, those comparisons can indicate whether an intervention changes the oxygen-delivery potential or broader physiological performance of the blood or tissue-engineered construct.